Literature DB >> 26710020

Patients' Preferences for Treatment for Dupuytren's Disease: A Discrete Choice Experiment.

Hester J Kan1, Esther W de Bekker-Grob, Eva S van Marion, Guido W van Oijen, Christianne A van Nieuwenhoven, Chao Zhou, Steven E R Hovius, Ruud W Selles.   

Abstract

BACKGROUND: Although in modern medicine, patients' preferences are important, these have never been defined for characteristics of Dupuytren treatment. This study determines these patients' preferences using a discrete choice experiment.
METHODS: A multicenter discrete choice experiment study was conducted among patients with Dupuytren's disease who had been treated previously. Patients were asked about their preferences for attributes of Dupuytren treatments using scenarios based on treatment method, major and minor complication rates, recurrence rates, convalescence, residual extension deficit after treatment, and aesthetic results. The relative importance of these attributes and the tradeoffs patients were willing to make between them were analyzed using a panel latent class logit model.
RESULTS: Five-hundred six patients completed the questionnaire. All above-mentioned attributes proved to influence patients' preferences for Dupuytren treatment (p < 0.05). Preference heterogeneity was substantial. Men who stated they performed heavy labor made different tradeoffs than women or men who did not perform heavy labor. In general, recurrence rate (36 percent) and extension deficit (28 percent) were the most important attributes in making treatment choices, followed by minor complication rate (13 percent). Patients accepted an increase in recurrent disease of 11 percent if they could receive needle aponeurotomy treatment instead of limited fasciectomy.
CONCLUSIONS: This study confirms the importance of low recurrence rates and complete contracture corrections, but also emphasizes the significance of low complication rates. Convalescence was not an attribute, which scored high. The preference heterogeneity shows that patient consultations need to be targeted differently, which may result in different treatment decisions, depending on patient characteristics and preferences.

Entities:  

Mesh:

Year:  2016        PMID: 26710020     DOI: 10.1097/PRS.0000000000001878

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  7 in total

1.  Dupuytren Disease Management Trends: A Survey of Hand Surgeons.

Authors:  Logan Carr; Brett Michelotti; Morgan Brgoch; Randy Hauck; John Ingraham
Journal:  Hand (N Y)       Date:  2018-07-25

2.  Using Latent Class Analysis to Model Preference Heterogeneity in Health: A Systematic Review.

Authors:  Mo Zhou; Winter Maxwell Thayer; John F P Bridges
Journal:  Pharmacoeconomics       Date:  2018-02       Impact factor: 4.981

3.  Skin Graft Review in Dermofasciectomy for Dupuytren's Contracture within 48 Hours: Challenging Historical Practice.

Authors:  Saif Akhter Ansari; James Andrew Kennedy; Fizan Younis
Journal:  J Hand Microsurg       Date:  2021-03-23

4.  Discrete Choice Experiments in Health Economics: Past, Present and Future.

Authors:  Vikas Soekhai; Esther W de Bekker-Grob; Alan R Ellis; Caroline M Vass
Journal:  Pharmacoeconomics       Date:  2019-02       Impact factor: 4.981

5.  Versatility of percutaneous needle fasciotomy for Dupuytren's disease across a spectrum of disease severity: A single-surgeon experience of 118 rays.

Authors:  Manal I A Patel; Irshad A Patel
Journal:  JPRAS Open       Date:  2020-11-30

6.  Dupuytren's disease: using needles more across the world.

Authors:  David Warwick; Paul Nm Werker; Gary Pess; Hitoshi Hirata; David J Hunter-Smith
Journal:  J Hand Surg Eur Vol       Date:  2021-09-09

7.  Comparative Effectiveness of Needle Aponeurotomy and Collagenase Injection for Dupuytren's Contracture: A Multicenter Study.

Authors:  Chao Zhou; Steven E R Hovius; Adriana J Pieters; Harm P Slijper; Reinier Feitz; Ruud W Selles
Journal:  Plast Reconstr Surg Glob Open       Date:  2017-09-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.